SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...
Hosted on MSN
DexCom reports strong Q1 as OTC CGMs reach new users
DexCom posted better-than-expected Q1 2026 results, with revenue up 15% year-over-year on strong uptake of its G7 continuous glucose monitor and expanded coverage for type 2 diabetes patients not ...
The device is similar to existing prescription CGMs. Users pair the wearable sensor with an application, put it on their arm and receive a continuous stream of glucose data on their smartphone or ...
Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
Blood glucose giant Dexcom has used CES 2024 to announce a new continuous glucose monitor (CGM) designed specifically for Type 2 diabetics who don’t use insulin – Dexcom Stelo. The Stelo still ...
DexCom, Inc. DXCM is scheduled to report third-quarter 2025 resultson Oct. 30, after the closing bell. In the last reported quarter, the company’s adjusted earnings per share (EPS) of 48 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results